Biohaven Pharmaceutical said on May 23 the company’s experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.
https://www.pharmalive.com/wp-content/uploads/2021/12/Biohavens-migraine-therapy-shows-rapid-pain-relief-in-late-stage-study-Reuters-12-6-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-23 11:43:502022-05-23 12:15:19Biohaven’s drug for neurological disease fails late-stage study